Navigation Links
New Study Shows Cloning from Dried Cells Now Possible
Date:9/8/2008

.

Dr. Loi also noted that the new technology also could assist with conserving animals threatened with extinction by allowing for easy and inexpensive transportation and storage of cells of endangered species. "This could be invaluable, given we have no way of recovering these species once they're gone."

"These results validate the potential of our freeze-drying technology across a broad range of scientific, medical and commercial applications," said Dr. Amir Arav, DVM, PhD, Core Dynamics' founder and chief technology officer. "We look forward to working with the medical community to advance products for clinical use."

About Core Dynamics:

Core Dynamics is a privately held biotechnology company that is stretching the horizons of the science of cryopreservation. The company is active in the research and development of unique freezing, thawing and freeze drying technologies that are being applied in work with cell preservation, blood transfusion, and tissue and organ transplantation. The company has developed unique protocols, equipment and solutions for cryopreservation of cells and of tissues such as osteo-articular cartilage and of whole organs. Core Dynamics' Research and Development center is located in Ness Ziona, Israel, with a staff of over 30 research scientists and support personnel. Company management has wide experience in the fields of medicine, cryopreservation and cell biology. The company's commercial offices are located in Mt. Laurel, New Jersey. Core Dynamics hopes to develop additional applications through research partnerships involving its advanced cryopreservation technologies. For more information, visit http://www.coredynamics.com.

Media Contact:

Rachel Kessler

Lazar Partners

Cell: 917-660-0608

Office: 212-599-1265

E-mail: rkessler@lazarpartners.com


'/>"/>
SOURCE Core Dynamics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
2. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
3. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
4. Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
5. Study Suggests a Possible Way to Offset Chemobrain Memory Loss
6. Cytopia Commences Second Phase II Study in Brain Cancer
7. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
8. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
9. CDC Misses Target With Flawed MMR/Autism Study
10. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
11. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
Breaking Medicine Technology:Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Omega 3 fatty acids appear to impact AMD progression 8896 1Omega 3 fatty acids appear to impact AMD progression 8896 2Omega 3 fatty acids appear to impact AMD progression 8896 3The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 1The Leukemia 26 Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 49377 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 1Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 2Bioheart to Introduce Improved Heart Failure Monitoring Systems at Heart Failure Nurses Annual Meeting 49375 3
... SUNNYVALE, Calif., April 13 Pharmacyclics, In...egun treating patients in a Phase,1 dose-escalatio... PCI-32765,an orally available, selective inhibito...al treatment for patients with relapsed or refract... the first Btk selective inhibitor to,be tested in...
... NOVATO, Calif., April 13 Raptor Pharmaceuticals ...ard: RPTP) today announced the appointment of Patr...r ("CMO"). Dr. Rioux will be responsible for the c...nical-stage drug development programs. , , (Logo:...YM074LOGO ) , , Raptor,s clinical programs inc...
Other Medicine Technology:Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 2Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 3Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 4Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer 5
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)Late recurrence is a risk for some pediatric cancers, particularly Ewing sarcomas and tumors of the central nervous system, according to a new study published online December 4 in the Journal of the
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...developed a way to produce blood vessels by engine... Researchers at the University at Buffalo D...y that the bone marrow is an excellent source of a... applications. According to Dr. Stelios T....
...e University of Nottingham are amassing an arsenal... against the most deadly of hospital superbugs . .... Its defences are so strong it can resist most an...hcare Associated Infections (CHAI), with Dr Peter ...
...niversity researcher is experimenting with ways to...hat we like about our favourite snacks . S...nce and industry at K-State's College of Agricultu... this process can be used to make fibre-enriched f...
...found that women are the real bosses at home . ...s, wives have greater power in marriage problem-so... 72 married couples from Iowa, found that wives, o... not considering who raised the topic. As...
...ting dads will be given some tips on how to raise ... The British government is hoping that its 23milli...et technology to support parents will appeal to fa...w initiative, "Parent Know-How", parents will be a...
...ho killed his 25-year-old female neighbor was sent...of Alicia Ross by her neighbor Daniel Sylvester w...ousness, by an Ontario Superior Court judge who im...er in the death of Alicia Ross, intended to kill h...
Other Medicine News:Health News:New Blood Vessels can Be Created from Bone Marrow Stem Cells: Study 2Health News:The Hospital Superbugs 2Health News:The Hospital Superbugs 3Health News:Now, Fibre-enriched Tasty Snacks in the Making 2Health News:Women are the Real Bosses at Home 2Health News:Women are the Real Bosses at Home 3Health News:A Savage Murderer in Canada Gets Sentenced to Life 2
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
...al reference laboratory and a worldwide leader in ...UP offers an extensive test menu of highly complex... pathology. Owned by the University of Utah, ARUP ...e nation's university teaching hospitals and child...
Medicine Products: